Bibliography
- Czerepak EA, Ryser S. Drug approvals and failures: implications for alliances. Nat Rev Drug Discov 2008;7:197-8
- Zhang XS, Xiang BR. Discontinued drugs in 2007: cardiovascular drugs. Expert Opin Investig Drugs 2008;7(12):1817-28
- Spooner PH, Thai HM, Goldman S, et al. Thyroid hormone analog, DITPA, improves endothelial nitric oxide and beta-adrenergic mediated vasorelaxation after myocardial infarction. J Cardiovasc Pharmacol 2004;44(4):453-9
- Leitzbach D, Afkham F, Schäfer S, et al. Improvement of systolic and diastolic function in old SHR by long-term treatment with the new vasopeptidase inhibitor AVE7688 and the ACE inhibitor ramipril [abstract]. Hypertension 2003;42(4):643
- GAP-134/ZP1609 programme. Zealand Pharma product pipeline information. Available from: http://www.zealandpharma.com/Product-Pipeline/GAP-134_ZP1609 [Last accessed 22 April 2009]
- Actelion announces first quarter 2008 financial results, published 22 April 2008. Available from: http://www1.actelion.com/en/journalists/news-archive.page? newsId=1211488 [Last accessed 22 April 2009]
- Schäfer S, Kolkhof P. Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discov Today 2008;13(21/22):913-6
- The Pharmaprojects Database, Informa UK plc. Available from: http://www.pharmaprojects.com [Last accessed 2009 March]